RAFA OTC
Rafarma Pharmaceuticals, Inc.
1W: -13.5%
1M: +6.7%
3M: +60.0%
YTD: +17.0%
1Y: -33.3%
3Y: -86.1%
5Y: -97.4%
$0.03
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$44K
+100.1% ▲
5Y CAGR: -66.4%
Capital Expenditures
$44K
-100.1% ▼
5Y CAGR: -67.0%
Free Cash Flow
$0
+0.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$5K
+100.0% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $184K | $10K | $5M | $273K | $266K |
| Depreciation & Amort. | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$299K | $3M | $6M | $18M | $137K |
| Other Non-Cash Items | -$5M | $3M | $9M | -$69M | -$282K |
| Operating Cash Flow | -$9M | $3M | $19M | -$51M | $44K |
| — Investing Activities — | |||||
| Capital Expenditures | $0 | $0 | -$12M | $51M | $0 |
| Acquisitions (Net) | $8M | $7M | $355K | $33M | $2K |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$1K | -$100K | $1K | -$51M | $0 |
| Investing Cash Flow | $8M | $7M | -$12M | $33M | $2K |
| — Financing Activities — | |||||
| Net Debt Issuance | -$450K | -$2M | -$791K | -$909K | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$5M | -$3M | $0 | $0 | $0 |
| Other Financing | $9M | $96K | -$2M | $712K | -$50K |
| Financing Cash Flow | $3M | -$5M | -$3M | -$197K | -$50K |
| Net Change in Cash | $5M | $8M | $4M | -$18M | -$5K |
| Cash End of Period | $5M | $14M | $18M | $82K | $77K |
| Free Cash Flow | -$9M | $3M | $7M | $0 | $0 |